Department of Radiology, University of Washington Medical Center, 1959 NE Pacific, Seattle, WA 98195, USA.
Eur Radiol. 2011 Aug;21(8):1609-17. doi: 10.1007/s00330-011-2094-6. Epub 2011 Feb 27.
To predict the probability of malignancy for MRI-detected breast lesions with a multivariate model incorporating patient and lesion characteristics.
Retrospective review of 2565 breast MR examinations from 1/03-11/06. BI-RADS 3, 4 and 5 lesions initially detected on MRI for new cancer or high-risk screening were included and outcomes determined by imaging, biopsy or tumor registry linkage. Variables were indication for MRI, age, lesion size, BI-RADS lesion type and kinetics. Associations with malignancy were assessed using generalized estimating equations and lesion probabilities of malignancy were calculated.
855 lesions (155 malignant, 700 benign) were included. Strongest associations with malignancy were for kinetics (washout versus persistent; OR 4.2, 95% CI 2.5-7.1) and clinical indication (new cancer versus high-risk screening; OR 3.0, 95% CI 1.7-5.1). Also significant were age > = 50 years, size > = 10 mm and lesion-type mass. The most predictive model (AUC 0.70) incorporated indication, size and kinetics. The highest probability of malignancy (41.1%) was for lesions on MRI for new cancer, > = 10 mm with washout. The lowest (1.2%) was for lesions on high-risk screening, <10 mm with persistent kinetics.
A multivariate model shows promise as a decision support tool in predicting malignancy for MRI-detected breast lesions.
建立一个包含患者和病灶特征的多变量模型,以预测 MRI 检测到的乳腺病变的恶性概率。
回顾性分析 2003 年 1 月至 2006 年 11 月期间 2565 例乳腺 MRI 检查。纳入最初在 MRI 上发现的新癌症或高危筛查的 BI-RADS 3、4 和 5 级病灶,通过影像学、活检或肿瘤登记处的关联来确定结果。变量包括 MRI 的适应证、年龄、病灶大小、BI-RADS 病灶类型和动力学。使用广义估计方程评估与恶性肿瘤的相关性,并计算病灶恶性肿瘤的概率。
共纳入 855 个病灶(155 个恶性,700 个良性)。与恶性肿瘤相关性最强的是动力学(洗脱与持续;OR 4.2,95%CI 2.5-7.1)和临床适应证(新发癌症与高危筛查;OR 3.0,95%CI 1.7-5.1)。年龄≥50 岁、病灶大小≥10mm 和病灶类型肿块也有显著意义。最具预测性的模型(AUC 0.70)纳入了适应证、大小和动力学。在 MRI 上发现的新癌症、病灶大小≥10mm 且出现洗脱的病灶恶性概率最高(41.1%)。在高危筛查中发现的、病灶大小<10mm 且动力学持续的病灶恶性概率最低(1.2%)。
多变量模型有望成为预测 MRI 检测到的乳腺病变恶性肿瘤的决策支持工具。